Kratom extracts are being promoted for inhalation as an alternative to tablets, powders and teas, but claims that vaping the substance is safer, more effective or free from harmful chemicals are not established by reliable medical evidence.
Kratom is derived from the leaves of Mitragyna speciosa, a tropical tree native to Southeast Asia. Its leaves contain psychoactive compounds, including mitragynine and 7-hydroxymitragynine, which can affect the brain and nervous system.
The US Food and Drug Administration (FDA) has warned about kratom-related products because of potential health risks, including liver toxicity, seizures and substance use disorder. The agency says no kratom-containing drug has been approved for medical use in the United States.
Safety of inhaling kratom extracts remains uncertain
Vaping involves heating a substance to produce an aerosol that is inhaled. Unlike combustion, the process does not necessarily burn the material, but that does not mean the resulting aerosol is harmless.
Claims that vaping kratom extract avoids the harmful substances associated with smoking, causes fewer side effects or delivers a more predictable effect require evidence specific to the substance and the method of inhalation.
The available evidence cited by the FDA identifies several concerns about kratom products, but it does not establish that inhaling kratom extracts is safe. The effects of a product can also depend on its chemical composition, concentration and any other ingredients it contains.
The speed at which a substance takes effect is not, on its own, evidence that it is safer or more beneficial. Nor does the absence of visible smoke establish that a product cannot harm the respiratory system.
Product composition and contamination
Kratom products can vary in composition and concentration. The FDA has previously warned about products contaminated with Salmonella or containing concerning levels of heavy metals, highlighting the importance of product quality and manufacturing controls.
A label describing an extract as pure or natural does not independently establish its safety. Laboratory testing may provide information about the ingredients and contaminants in a tested sample, but it cannot by itself prove that inhaling the product is safe or establish its long-term effects.
Concentrated kratom-related compounds also require particular caution. In July 2025, the FDA issued warning letters to companies marketing products containing concentrated 7-hydroxymitragynine, commonly known as 7-OH, citing concerns about their potential harm and unsupported claims about their benefits. The agency distinguished these concentrated products from kratom leaf products containing naturally occurring trace amounts of the compound.
Medical benefits have not been established
Kratom products are marketed for a range of claimed effects, including pain relief and stress reduction. However, marketing claims should not be confused with established medical benefits.
The FDA has warned consumers against using kratom because of the risk of serious adverse events and has taken action against companies making unproven therapeutic claims. The agency has not approved kratom as a treatment for pain, anxiety or other medical conditions.
The safety of vaping kratom extract, including its potential effects on the lungs and the likelihood of dependence, cannot be established simply by comparing it with oral products or combustible tobacco.
For consumers, the central issue is the lack of sufficient evidence to support claims that inhaled kratom extracts are a safe alternative to other forms of consumption. Until reliable research establishes their risks and effects, claims of superior safety or effectiveness should be treated with caution.
